...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Straightforward palladium-mediated synthesis and biological evaluation of benzo[j]phenanthridine-7,12-diones as anti-tuberculosis agents.
【24h】

Straightforward palladium-mediated synthesis and biological evaluation of benzo[j]phenanthridine-7,12-diones as anti-tuberculosis agents.

机译:直接用钯介导的苯并[j]菲啶-7,12-二酮作为抗结核药的合成和生物学评估。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

In 1991, WHO recognized the resurgence of tuberculosis as a global health problem. Although modern chemotherapy is effective against the causative pathogen Mycobacterium tuberculosis, the current drug regimens have failed to eradicate the disease. The success of the pathogen, partially attributed to drug resistance, necessitates the development of novel anti-tuberculosis drugs. Benzo[j]phenanthridine-7,12-diones, tetracyclic derivatives of the natural product benz[g]isoquinoline-5,10-dione, were conveniently synthesized via palladium-catalyzed intramolecular cyclization of N-methanesulfonyl-3-bromo-2-(arylamino)methyl-1,4-naphthoquinones. Here we report on the bioactivity of eight benzo[j]phenanthridine-7,12-dione derivatives as candidate drug molecules against M. tuberculosis and on their cytotoxicity on C3A human hepatocytes. The strongest antimicrobial activity (as detected by growth inhibition of bacteria, using luminometry and BACTEC 460-TB) and lowest cytotoxicity was found for 3-methylbenzo[j]phenanthridine-7,12-dione 5e, which was also effective in targeting intracellular M.?tuberculosis (in murine J774 macrophages) and was not genotoxic for C3A hepatocytes.
机译:1991年,世卫组织认识到结核病的复活是全球健康问题。尽管现代化学疗法对引起病原体的结核分枝杆菌是有效的,但是目前的药物疗法未能根除该疾病。病原体的成功部分归因于耐药性,因此有必要开发新型抗结核药。天然产物苯并[g]异喹啉-5,10-二酮的四环衍生物苯并[j]菲啶-7,12-二酮可通过钯催化N-甲磺酰基-3-溴-2-的分子内环化反应方便地合成。 (芳基氨基)甲基-1,4-萘醌。在这里,我们报告了八种苯并[j]菲啶-7,12-二酮衍生物作为抗结核分枝杆菌的候选药物分子的生物活性及其对C3A人肝细胞的细胞毒性。对于3-甲基苯并[j]菲啶-7,12-dione 5e,发现最强的抗菌活性(通过光度法和BACTEC 460-TB通过细菌的生长抑制来检测)和最低的细胞毒性,这对于靶向细胞内M也有效结核病(在鼠类J774巨噬细胞中),对C3A肝细胞没有遗传毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号